Amylyx Pharmaceuticals (AMLX) Cash from Operations (2021 - 2026)

Amylyx Pharmaceuticals' Cash from Operations history runs 6 years deep, the most recent figure standing at 36882000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 7.39% year-over-year to 36882000.0 in Q1 2026; TTM through Mar 2026 was 120401000.0, a 41.83% increase from a year earlier, with the FY2025 full-year figure at 123343000.0, up 26.43% from the prior year.
• Cash from Operations fell to 36882000.0 in Q1 2026 per AMLX's latest filing, from 27903000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 13551000.0 in Q4 2023 and bottomed at 66580000.0 in Q2 2024.
• The 5-year median for Cash from Operations is 36882000.0 (2026), against an average of 29166117.65.
• Across the five-year window, Cash from Operations jumped 127.27% in 2023 and sank 8043.97% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 49697000.0 in 2022, then jumped by 127.27% to 13551000.0 in 2023, then slumped by 535.45% to 59008000.0 in 2024, then jumped by 52.71% to 27903000.0 in 2025, then plunged by 32.18% to 36882000.0 in 2026.
• Per Business Quant, the three latest AMLX Cash from Operations figures stand at 36882000.0 (Q1 2026), 27903000.0 (Q4 2025), and 30368000.0 (Q3 2025).